Already weary from the Covid-19 pandemic, governments and businesses are now facing a new public health challenge. Monkeypox is spreading rapidly in the United States and globally. Although this infectious disease presents significantly less risk than Covid-19, employers should be prepared to address potential infections in their workforces and communities.
The monkeypox virus is a relative of smallpox and causes systemic symptoms, including fever, swollen lymph nodes, muscle aches, and a characteristic rash that progresses from blisters to pustules. The Jynneos vaccine, initially designed to protect against smallpox, can lower risk of infections and decrease symptoms if given within two weeks of exposure. It has been in short supply in the United States, but supplies are expected to increase in the coming months. Monkeypox testing is now available through health departments and public labs.
Here are some key considerations for employers:
1. The risk of…
This article was written by Jeff Levin-Scherz and originally published on hbr.org